CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: CML LSCs with a CD34+CD38− phenotype have been shown to express CD26, a cytokine-targeting surface enzyme that is not detectable on normal stem cells or LSCs in other hematological malignancies [25,26].